Compare AGRZ & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRZ | GRI |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.0M |
| IPO Year | 2024 | 2020 |
| Metric | AGRZ | GRI |
|---|---|---|
| Price | $2.93 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | ★ 198.1K | 44.3K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.18 |
| 52 Week High | $5.34 | $64.12 |
| Indicator | AGRZ | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 35.56 |
| Support Level | $2.71 | $1.36 |
| Resistance Level | $3.78 | $2.63 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 7.70 | 10.29 |
Agroz Inc is a vertically integrated agricultural technology (AgTech) company focused on designing, innovating, developing, building, operating and managing large, commercial-scale, industrial-grade indoor CEA vertical farms using CEA practices. Its mission is to improve food safety, food security, and sustainability for society by creating a reliable, accessible food supply through its AgTech products and services. CEA vertical farming is an agricultural method involving crop cultivation through vertically stacked layers in a controlled indoor environment. CEA practices are defined by growing produce in spaces where environmental conditions can be controlled and manipulated to match the needs of specific plants.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.